Satellite Symposia
AML, Diseases, Therapies, Adverse Events, Cell Lineage, Myeloid Malignancies, Clinically relevant
Chairs:
Harry P. Erba, MD, PhD, Duke University Medical Center
and
Naval Daver, MD, The University of Texas, M.D. Anderson Cancer Center
Disclosures:
Daver: Bristol-Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Karyopharm: Research Funding; Servier: Research Funding; Genentech: Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novimmune: Research Funding; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Trovagene: Research Funding; Fate Therapeutics: Research Funding; ImmunoGen: Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Jazz: Consultancy, Membership on an entity's Board of Directors or advisory committees; Trillium: Consultancy, Membership on an entity's Board of Directors or advisory committees; Syndax: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; KITE: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding.
Speakers:
Gail J. Roboz, MD, Weill Medical College of Cornell University New York-Presbyterian Hospital, Weill Cornell Medicine, The New York Presbyterian Hospital
and
Tara Lin, MD, University of Kansas Medical Center
Disclosures:
Roboz: Sandoz: Consultancy; Takeda: Consultancy; Trovagene: Consultancy; Epizyme: Consultancy; Helsinn: Consultancy; MEI Pharma: Consultancy; Cellectis: Research Funding; Jasper Therapeutics: Consultancy; Abbvie: Consultancy; Pfizer: Consultancy; Novartis: Consultancy; Janssen: Consultancy; Celgene: Consultancy; Astex: Consultancy; Amphivena: Consultancy; Agios: Consultancy; Amgen: Consultancy; GlaxoSmithKline: Consultancy; Bristol Myers Squibb: Consultancy; Mesoblast: Consultancy; Actinium: Consultancy; Argenx: Consultancy; Astellas: Consultancy; Daiichi Sankyo: Consultancy; AstraZeneca: Consultancy; Orsenix: Consultancy; Otsuka: Consultancy; Array BioPharma: Consultancy; Bayer: Consultancy; Celltrion: Consultancy; Eisai: Consultancy; Jazz: Consultancy; Roche/Genentech: Consultancy. Lin: Pfizer: Research Funding; Prescient Therapeutics: Research Funding; Seattle Genetics: Research Funding; Tolero Pharmaceuticals: Research Funding; Trovagene: Research Funding; Ono Pharmaceutical: Research Funding; Mateon Therapeutics: Research Funding; Jazz: Research Funding; Incyte: Research Funding; Gilead Sciences: Research Funding; Abbvie: Research Funding; Genetech-Roche: Research Funding; Astellas Pharma: Research Funding; Celyad: Research Funding; Celgene: Research Funding; Bio-Path Holdings: Research Funding; Aptevo: Research Funding.
This activity has been developed in collaboration with The University of Texas MD Anderson Cancer Center.
A wave of new science in acute myeloid leukemia (AML) has decisively ended the era of conventional cytarabine-based chemotherapy as the lone standard of care. This dramatic change was fueled by two developments: a greater understanding of AML biology and the various factors that define different AML subtypes and populations; and the rapid emergence and validation of multiple novel therapeutics across the disease spectrum. As a consequence, modern AML treatment protocols now include the use of novel cytotoxic formulations, epigenetic agents, targeted agents (FLT3, IDH1/2, and BCL-2 inhibitors), and novel antibodies, with therapeutic decisions based on a close clinical reading of baseline disease- and patient-related features.
Led by a panel of expert clinicians this PeerView “How I Think, How I Treat” activity will explore the practice-changing evidence that has validated innovative approaches to managing high-risk AML (eg, secondary AML); the use of targeted agents in mutation-defined disease and older populations; and the steady progress being made with antibody-based options for AML. Throughout the scientific sessions, the experts will highlight their personal reflections on state-of-the-art AML care with a goal of illustrating how their own intra-institutional practices were changed and improved with the use of novel therapeutics. Join us for this exciting event and learn how leading clinicians have adapted their own practices when managing patients with AML.
denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.